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Abstract
Use of the diabetes type II drug Metformin is associated with a moderately lowered risk of cancer incidence in
numerous tumor entities. Studying the molecular changes associated with the tumor-suppressive action of Metformin
we found that the oncogene SOX4, which is upregulated in solid tumors and associated with poor prognosis, was
induced by Wnt/β-catenin signaling and blocked by Metformin. Wnt signaling inhibition by Metformin was
surprisingly speciﬁc for cancer cells. Unraveling the underlying speciﬁcity, we identiﬁed Metformin and other
Mitochondrial Complex I (MCI) inhibitors as inducers of intracellular acidiﬁcation in cancer cells. We demonstrated that
acidiﬁcation triggers the unfolded protein response to induce the global transcriptional repressor DDIT3, known to
block Wnt signaling. Moreover, our results suggest that intracellular acidiﬁcation universally inhibits Wnt signaling.
Based on these ﬁndings, we combined MCI inhibitors with H+ ionophores, to escalate cancer cells into intracellular
hyper-acidiﬁcation and ATP depletion. This treatment lowered intracellular pH both in vitro and in a mouse xenograft
tumor model, depleted cellular ATP, blocked Wnt signaling, downregulated SOX4, and strongly decreased stemness
and viability of cancer cells. Importantly, the inhibition of Wnt signaling occurred downstream of β-catenin,
encouraging applications in treatment of cancers caused by APC and β-catenin mutations.
Introduction
Epidemiological studies have established that regular use
of Metformin lowers the incidence risk for many cancer
entities, including colorectal adenocarcinoma1. Also, Met-
formin has been shown to cooperate in elimination of
cancer cells in combination with a number of other
drugs2,3, as well as with radiotherapy4,5. Metformin repre-
sents a universal, but very weak, anticancer drug. Meta-
analyses of multiple studies support its antitumor effect,
affecting, for example, cancers of lung6, prostate7, and
endometrium8. However, in some studies no improvement
was observed, e.g., with non-small cell lung cancer
(NSCLC)9.
The mechanism for Metformin’s anti-cancer speciﬁcity
remains unclear. It has been proposed that the anti-
diabetic property of Metformin might also account for its
anticancer effect. While previous studies have suggested
that activation of AMPK (AMP-activated protein kinase)
mediates the anticancer action of Metformin10,11, this has
remained controversial12,13. In addition, Metformin can
inhibit mitochondrial GPD2 (Glycerol-3-Phosphate
Dehydrogenase 2)14. A characteristic feature of Metfor-
min and other biguanidine-type drugs is their ability to
reduce cellular ATP level by inhibition of mitochondrial
complex I (MCI) accompanied by compensatory increase
rate of glycolysis in sensitive cells15. In general, MCI
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inhibitors are known for their anticancer properties16–18.
A moderate inhibition of MCI with therapeutical doses of
MCI inhibitors causes no side effects in routine medical
practice (Metformin, Phenformin, and Papaverine).
However, a disadvantage of Metformin as an anticancer
drug is a necessity to apply it at very high concentrations
in in vitro experiments to achieve substantial effects. To
reach similar outcome in cancer patients, the drug has
to be applied at doses that might trigger lactic acidosis
as a side-effect. Insights into Metformin’s anticancer
mechanism could help to suggest more effective drugs
with similar but enhanced properties.
Since Metformin affects tumor cells from multiple
tissue entities, this suggests that there are some under-
lying common molecular markers. Evaluation of these
markers would help monitoring molecular changes
caused by Metformin. The most pronounced anticancer
effects for Metformin have been reported for colorectal
adenocarcinoma cases1. It is well-established that in
many instances colorectal cancer is caused by aberrant
Wnt signaling19,20. At the same time, SOX4 (SRY (Sex
Determining Region Y)-box 4), a transcription factor
and oncogene expressed in many types of tumors21,22,
has been found to be a prognostic marker of poor out-
come for colon cancer patients23. These observations
point to a probable link between Metformin, Wnt sig-
naling and SOX4. High expression levels of SOX4 cor-
relate with cancer patients mortality rates, regardless of
other clinical parameters21. Conversely, it has been
demonstrated that knockdown of the SOX4 gene in
xenograft model suppresses tumor growth24. Normal
SOX4 expression is limited to embryonic cells and
some adult tissues such as pancreas, intestine, and skin.
It is also expressed in a number of human non-cancer
cell lines of embryonic origin25. SOX4 expression is
linked to cell migration, proliferation, Epithelial-to-
Mesenchymal transition (EMT) and metastasis forma-
tion26. Thus, SOX4 would be a candidate for a universal
oncogene that is independent of a tumor entity, and at
the same time is expressed in non-cancer cells of
embryonic origin. These two important features could
be used to assess both speciﬁcity and efﬁciency of tested
cancer-suppressing treatments.
Upregulation of Wnt signaling is a strong cancer-
driving force for multiple types of malignancies19, and in
particular, is a primary cause of colon cancer20. Pre-
dominant reasons for such Wnt signaling upregulation
are loss-of-function mutations for APC, which promotes
β-catenin degradation. As a result, β-catenin protein
accumulates and, upon binding LEF/TCF transcription
factors and co-activators of transcription CBP/p300,
forms an ‘activator complex’. This complex binds to LEF/
TCF binding sites at promoters of Wnt target genes.
Abnormal accumulation of β-catenin therefore causes
overexpression of speciﬁc Wnt target genes, including
AXIN2, and a number of potential oncogenes27. In addi-
tion, a variety of stabilizing mutations in β-catenin gene
cause similar effects as APC mutations. β-catenin and
APC mutations account for 95% incidences of colorectal
cancer. Mutations resulting in β-catenin accumulation are
not limited to colon cancer, and often found in tumors of
other origin: liver (hepatocellular carcinoma28), kidney29,
ovary30, prostate31, brain (medulloblastoma32), endo-
metrial cancer33 and thyroid gland34. In addition, Wnt
signaling is a major positive contributor in multiple can-
cer stem cells functions27,35 and also is a driving force of
lung adenocarcinoma36.
Multiple attempts have been made to develop drugs
inhibiting Wnt signaling (reviewed by Novellasde-
munt et al.,20). Only a few of the found drugs could target
β-catenin/TCF interactions, to block Wnt signaling at the
level of β-catenin37. A main pitfall of these drugs, how-
ever, is the absence of speciﬁcity towards cancer cells, and
accompanying side effects.
In this study, we addressed the mechanism of the uni-
versal anticancer properties of Metformin and discovered
its ability to block Wnt signaling speciﬁcally in cancer
cells. We applied these ﬁndings to develop a new cancer
cell speciﬁc strategy for Wnt/β-catenin signaling inhibi-
tion that exploits a characteristic feature of cancer cell
metabolism, - the Warburg effect38. We found that this
strategy resulted in consequent cancer cells elimination
without causing any signiﬁcant effects in non-cancer cells.
Results
Metformin inhibits Wnt/β-catenin signaling
Wnt signaling can be induced in cultured cells by
applying Wnt3a protein and monitored either by mea-
suring β-catenin protein stabilization or induction of its
immediate downstream target gene AXIN2. We found
that Metformin inhibits Wnt signaling as monitored by
AXIN2 expression, but only moderately affects levels of β-
catenin protein accumulation (Fig. 1a). Moreover, we
found that the expression of an oncogene SOX4, which we
identiﬁed to be Wnt3a-inducible, and with similar kinetics
of mRNA and protein levels induction to the Wnt target
gene AXIN2 (Supplementary Fig. S1a-b), was also inhib-
ited by Metformin (Fig. 1a-c). Treatment with siβ-catenin
RNA prevented SOX4 induction upon Wnt3a treatment,
and conversely, SOX4 was induced by β-catenin over-
expression (Supplementary Fig. S1c-d). However, in can-
cer cell lines DLD1, HCT116, and H1975, siβ-catenin did
not affect SOX4 expression (Supplementary Fig. S1e),
indicating that SOX4 expression does not universally
require Wnt signaling. Yet, in these cell lines, Metformin
still blocked SOX4 (Fig. 1b-c), suggesting that Metformin
can affect SOX4 expression also independently of Wnt
signaling. Interestingly, Metformin had no inhibiting
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effect on SOX4 and AXIN2 levels in non-cancer cell lines
(HEK293T, MRC5, and C2C12, Fig. 1d-e). We conclude
that expression of SOX4 is Wnt-inducible and sensitive to
Metformin preferentially in cancer cells.
Next, we addressed the question whether regular intake
of Metformin by diabetic cancer patients might have an
impact on expression of SOX4 and other Wnt target genes
in their tumor tissue. For this purpose, we analyzed a lung
cancer patient cohort, as it has been shown that lung
cancer is associated with aberrant Wnt signaling39. No
signiﬁcant changes in mean values of SOX4 and AXIN2
between non-diabetic and diabetic Metformin-taking lung
cancer patients were detected (Supplementary Table S1).
However, there was a signiﬁcant correlation between
SOX4 and AXIN2 mRNA levels in tumor tissues in the
group of non-diabetic lung cancer patients (Spearman’s
rank correlation coefﬁcient ρ= 0.47, P < 0.0001). This
correlation was lost in tumor samples of the diabetic
Metformin-taking lung cancer cohort (Fig. 1f). Since
SOX4 expression and EMT are common mechanisms
underlying metastasis26, we tested whether levels of EMT
markers in lung tumor samples were also affected by
Metformin intake. Indeed, there was a signiﬁcant corre-
lation between levels of AXIN2 and the EMT markers
VIM (Vimentin) and ZEB1 (Zinc Finger E-Box Binding
Homeobox 1), which again was lost in tumor samples from
Metformin-taking lung cancer patients (Supplementary
Fig. S2). Interestingly, within the Metformin-taking
cohort, higher initial levels of AXIN2 mRNA (‘high Wnt
group’) correlated with prolonged survival (P= 0.046)
(Fig. 1g). We speculate that the high AXIN2 group
represents Wnt-addicted tumors, suggesting that patients
with higher Wnt signaling might particularly beneﬁt from
Metformin treatment.
Metformin treatment abolishes TCF4/β-catenin/CBP-p300
activation complex formation
Next, we addressed whether TCF4 (T-cell Factor 4, a
member of LEF/TCF protein family) remains bound to the
SOX4 promoter upon Metformin treatment. We inspected
the SOX4 gene locus and found four putative sites for LEF/
TCF transcription factors binding (containing the con-
sensus sequence CAAAG40) within the SOX4 promoter
region. Another four putative TCF4 binding sites were
found in close proximity downstream in the gene body
(Fig. 2a). By chromatin immunoprecipitation assay (ChIP)
SOX4
β-catenin
Wnt3a
H
17
03
R
el
at
iv
e 
m
R
N
A 
le
ve
ls
 
+- +
control Metformin
SOX4 AXIN2
α-tubulin
-
a
SOX4
α-tubulin
Wnt3a
H
12
99
R
el
at
iv
e 
m
R
N
A 
le
ve
ls
 
- + - +
control Metformin
β-catenin
0
40
80
120
160
40
30
20
10
0
SOX4
α-tubulinD
LD
1
R
el
at
iv
e 
m
R
N
A
 le
ve
ls
0
Metformin- +
2
4
6
R
el
at
iv
e 
m
R
N
A
 le
ve
ls
H
C
T1
16
0
- +
20
40
60
SOX4 AXIN2
b c
H
19
75
- +
SOX4
α-tubulin
Metformin
d
SOX4
α-tubulin
Metformin
M
R
C
5
- +
H
E
K
29
3T
- +
Metformin
SOX4
α-tubulin
ρ = 0.47
P < 0.0001
Non-diabetic lung cancer patients, n = 66
0.125 0.25 0.5 1 2 4 8 16 32
0.125
0.25
0.5
1
2
4
8
16
Relative AXIN2 mRNA levels (log2)
R
el
at
iv
e 
S
O
X
4
m
R
N
A
le
ve
ls 
(l o
g2
)
Metformin-taking diabetic lung cancer 
patients, n = 42
ρ = 0.10, ns
0.125 0.25 0.5 1 2 4 8 16 32
0.125
0.25
0.5
1
2
4
8
16
R
el
at
iv
e 
S
O
X
4
m
R
N
A
le
ve
ls 
(lo
g2
)
Relative AXIN2 mRNA levels (log2)
f
g
R
el
at
iv
e 
m
R
N
A 
le
ve
ls
 
AXIN2
Wnt3a - + - +
control Metformin
MRC5
3.0
2.5
2.0
1.5
1.0
0.5
0
40
Wnt3a
R
el
at
iv
e 
m
R
N
A 
le
ve
ls
 
- + - +
control Metformin
35
30
25
20
15
5
10
0
C2C12
e
100
75
50
25
0
0 1 2 3 4 5 6 7 8 9
Time (years)
O
ve
ra
ll 
su
rv
iv
al
 (%
)
AXIN2 > 1.02, n = 28
AXIN2 ≤ 1.02, n = 14
P = 0.046
*
Fig. 1 Metformin inhibits Wnt signaling. a–e Levels of the indicated
mRNAs and proteins were monitored in the indicated cell lines by
qRT-PCR or WB, respectively. Error bars represent mean values ± SD. f
Non-linear Spearman’s rank correlation analysis of SOX4 mRNA
expression levels with Wnt signaling (AXIN2) in tumor tissue samples
from lung cancer patients, non-diabetic or Metformin-taking diabetic.
ρ Spearman’s rank coefﬁcient for non-linear correlation; P < 0.0001
(****); ns - not signiﬁcant. g Kaplan–Meier overall survival curves of
the Metformin-taking diabetic lung cancer patient cohort stratiﬁed by
AXIN2 expression levels (mRNA threshold expression level= 1.02, log-
rank test, P= 0.046 (*)).
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immunoprecipitation with TCF4 antibody bound to agarose beads, and immunocomplexes were tested by WB with β-catenin antibody
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we found that, indeed, the proximal promoter of SOX4
gene (at position -400 from transcription start site (TSS))
strongly binds TCF4 upon treatment with Wnt3a. Similar
binding was detected to AXIN2, a positive control gene
for TCF4 binding41, in contrast to a negative control,
GAPDH gene. However, Metformin treatment completely
abolished TCF4 binding, for both SOX4 and AXIN2 genes
(Fig. 2b).
We then analyzed whether the mechanisms that have
been proposed to underlie the antidiabetic effect of
Metformin might also account for its anticancer proper-
ties. While previous studies have suggested that activation
of AMPK mediates the anticancer action of Metfor-
min10,11, this remains controversial12,13. In addition,
Metformin has been shown to inhibit mitochondrial
GPD214. In our experiments, however, neither siGPD2,
nor siAMPK interfered with the Metformin'sinhibiting
effect on SOX4 expression (Supplementary Fig. S3a-b).
Metformin has also been shown to reduce gene activation
in gluconeogenesis by promoting phosphorylation of the
histone acetyltransferase (HAT) CBP, but not of the
related HAT p30042. CBP (also known as CREB-binding
protein or CREBP) and p300 (p300 known as EP300 or
E1A binding protein p300), share 63% homology in their
sequences and structures and are involved in multiple
cellular processes functioning as transcriptional co-factors
and histone acetyltransferases43. It has been shown that
Metformin treatment causes phosphorylation of murine
CBP at Ser436 blocking its binding to promoters of glu-
coneogenesis enzymes genes, whereas p300, which has
Ala instead of Ser at this position, retains its activity42. We
assayed whether Metformin utilizes its effect on SOX4 in
similar fashion and exclusively prevents CBP binding at
the promoter of SOX4 gene over p300. We found that
Metformin treatment abrogated binding to the SOX4
promoter of both, CBP and p300 (Fig. 2c), arguing against
CBP as Metformin´s speciﬁc target in SOX4 inhibition.
Moreover, by Co-immunoprecipitation assay (Co-IP), we
found that TCF4/β-catenin complex formation is affected
by Metformin treatment in general, as this interaction
induced by Wnt3a, was disrupted by the drug (Fig. 2d).
DDIT3 is one of the key mediators of Wnt signaling
inhibition
The inhibition of TCF4 binding to target gene pro-
moters accompanied by removal of CBP/p300 suggested
that Metformin might induce some transcriptional
repressor. We focused on the stress response transcrip-
tion factor DDIT3 (DNA damage-inducible transcript 3,
CHOP, GADD153), since it is known to be Metformin-
inducible44 and inhibiting Wnt signaling via LEF/TCF
binding45. We found that in concentrations where Met-
formin induces DDIT3 protein (Supplementary Fig. S4a-
c), it repressed Wnt signaling (Supplementary Fig. S4d). In
a loss-of-function approach, siDDIT3 blocked the ability
of Metformin to inhibit SOX4 induction by Wnt3a (Fig. 3a
and Supplementary Fig. S5a). Using a DDIT3-mutant
H1975 cell line created by CRISPR/Cas9 gene editing, we
found that DDIT3 knockout completely abrogated SOX4
inhibition by Metformin (Fig. 3b and Supplementary
Fig. S4e). Conversely, DDIT3 overexpression in three
different cell lines using the Tet-on system inhibited
SOX4 expression, thus mimicking the effect of Metformin
(Fig. 3c). This suggests that DDIT3 induction directly
mediates SOX4 inhibition by Metformin. Indeed, the
DDIT3 inducers, Tunicamycin46 and Bortezomib47, also
blocked SOX4 expression (Fig. 3d and Supplementary
Fig. S6a-b). Additionally, consistent with inhibition of
SOX4, a gene promoting metastasis and cell invasion22,
both Metformin and Bortezomib signiﬁcantly reduced the
invasion characteristics of cancer cells induced with
Wnt3a treatment (Supplementary Fig. S6c).
Both Tunicamycin and Bortezomib induce endoplasmic
reticulum (ER) stress, and DDIT3 is a component med-
iating the Unfolded Protein Response (UPR)48. We
examined whether other key components of the UPR
might also mediate Metformin’s action. Indeed, targeting
the other UPR components (PERK, IRE1, ATF2, ATF4,
and ATF6) by siRNA also repressed Metformin´s ability
to block SOX4 induction by Wnt3a, with ATF6 being the
most prominent (Fig. 3e and Supplementary Fig. S5b).
Metformin and MCI inhibitors cause intracellular
acidiﬁcation and induce the UPR
How does Metformin induce the UPR? We and others49
observed that culture media from cells under Metformin
treatment tended to acidify. Hence, we hypothesized that
Metformin treatment might also disturb cells’ ability to
maintain the intracellular pH (pHi), thereby inducing ER
stress and the UPR. It is known that the extracellular pH
(pHe) in tumor microenvironment is reduced to as low as
~pH 5.5, and that acidosis is an important stress factor
and selection force for cancer cell somatic evolution50. To
test whether Metformin lowers the intracellular pH, we
generated a stable H1975 lung cancer and HEK293 con-
trol cell line expressing a pH-sensitive variant of GFP (EC-
GFP) (H1975EC-GFP and HEK293EC-GFP), whose ﬂuores-
cence is extinguished at low pH when excited at 488 nm,
but not at 405 nm (‘E488’ vs. ‘E405’)
51. Metformin treat-
ment strongly reduced emission at E488, but not at E405,
indicating lowering of pHi, and this was speciﬁc for the
H1975EC-GFP lung cancer cell line (Fig. 4a). We also
established a human colon cancer cell line DLD1
expressing a combination of pH sensitive EC-GFP, as a
pHi sensor, along with a pH-insensitive protein mCherry,
as a control ﬂuorescent protein (DLD1EC-GFP/mCHERRY).
Using this reporter cell line, we analyzed the pHi
dynamics with and without Metformin treatment. Cells
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were placed in slightly acidic medium (pH 6.5) mimicking
acidiﬁed tumor microenvironment. Without Metformin,
cancer cells predictably increased the pHi to compensate
lower pHe (Fig. 4b, control)52, however, in the presence of
Metformin the pHi was signiﬁcantly decreased.
Next, we assayed the pHi changes in tumor tissue
derived from human lung cancer H1975EC-GFP cells
xenotransplanted in nude mice that were given Metfor-
min orally, once the tumor growth was detected. A week
later after the treatment had started, mice were subjected
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to live imaging, and pH sensitive ﬂuorescence of tumor
cells was monitored, ﬁrst in vivo (Fig. 4c, bottom) and
then ex vivo, immediately after tumor excision (Fig. 4c,
top). We detected, both in vivo and ex vivo, a signiﬁcant
(P= 0.0179) pHi drop in tumor tissues of tested animals
that received Metformin compared to the control mice.
We conclude that Metformin signiﬁcantly decreases the
intracellular pH in cancer cells, both in vitro and in vivo.
How does the treatment with Metformin affect the pHi?
Metformin inhibits Mitochondrial Complex I (MCI) 4 and
hence ATP production, leading to compensatory increase in
glycolysis and acidiﬁcation due to lactic acid production.
We tested the effect on pHi of other known MCI inhibitors
and found that, similar to Metformin, all caused a pHi drop
(Supplementary Fig. S7a-b). However, this was not the case
with an inhibitor of Mitochondrial complex II (Supple-
mentary Fig. S7c), which produces less energy than complex
I. Of note, MCI inhibitors are known for their anticancer
properties16–18.
A common feature of cancer cells is a reversed pH
gradient, i.e., a higher pHi and a lower pHe than in normal
cells because their pHi homeostasis relies on extrusion of
H+ by ATP-consuming proton pumps53,54. In case of an
ATP deﬁcit, proton pumps function is impaired leading to
intracellular acidiﬁcation. This scenario predicts that
cancer cells might overcome Metformin inhibition when
extra glucose is provided to support glycolysis as an
alternative pathway for ATP production. Indeed, cell
culture medium pH-adjustment combined with elevated
glucose completely rescued SOX4 suppression by Met-
formin (Fig. 4d). This result is consistent with the earlier
observation that cancer cells are more sensitive to Met-
formin at lowered glucose levels49.
To address a question whether the intracellular acid-
iﬁcation alone would block Wnt signaling and cause
similar effects as MCI inhibitors, we tested drugs thought
to decrease pHi by affecting monocarboxylate transpor-
ters (MCT) and carbonic anhydrases (CA)54. We found
that a broad MCT inhibitor CHC (2-Cyano-3-(4-hydro-
xyphenyl)-2-propenoic acid) was able to decrease pHi
(Supplementary Fig. S8a), and this correlated with its Wnt
signaling inhibition ability (Supplementary Fig. S8b).
However, speciﬁc MCT-1 (AZD3965) or CA inhibitors
(Azetazolamide) were not able to drop the pHi or inhibit
Wnt signaling (Supplementary Fig. S8). We therefore
conclude that any treatment causing pHi drop would
inhibit Wnt signaling.
MCI inhibitor and ionophore drug combinations inhibit
Wnt signaling and cell viability
We reasoned that combined treatment with MCI inhi-
bitor and H+-ionophore could create an auto-enhancing
cycle of acidiﬁcation that would speciﬁcally target tumor
cells. The speciﬁcity of this treatment regime for cancer
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cells would come from (i) their reverse pH gradient and
(ii) that they rely mostly on glycolysis as a source of ATP
(the Warburg effect), thereby producing acidifying lactic
acid. Upon ionophore-induced extra-to-intracellular
proton leakage, cancer cells would consume more glu-
cose to aliment proton pumps counteracting acidiﬁcation,
thus producing even more lactic acid, and thereby esca-
lating cancer cells into hyper-acidiﬁcation and
ATP depletion. We named a principle comprised by this
cycle as a ‘Warburg Trap’ (Fig. 4e).
We tested this hypothesis by treatment of cancer and
non-cancer cell lines with selected drug combinations:
Nigericin (ionophore) with Rotenone (MCI inhibitor),
Salinomycin (ionophore) with Papaverine (MCI inhibitor),
and Monensin (ionophore) with Phenformin (MCI inhi-
bitor). We conﬁrmed that these drug combinations low-
ered pHi in vitro (Fig. 5a, and Supplementary Fig. S9a).
Predictably, the drug combinations cooperatively blocked
constitutive and Wnt3a-induced SOX4 expressions in
cancer cell lines (Fig. 5b-c, and Supplementary Fig. S9b-c),
and this effect was rescued in DDIT3−/− cells (Fig. 5d).
Additionally, we observed that DDIT3 was expressed
only transiently. When cells were treated with the drug
combinations for 24 h, DDIT3 protein induction was
detected simultaneously with SOX4 repression in H1299
cells. However, 24 h later (at 48 h post-treatment), DDIT3
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was undetectable (Supplementary Fig. S9c). Importantly,
SOX4 remained repressed, even in the absence of
detectable DDIT3.
Then, the drug combination treatment blocked aberrant
Wnt signaling in DLD1 cells bearing APC mutation, with
no effect in non-cancer cell lines (C2C12 and MRC5),
manifested by strong decrease of expression of Wnt target
genes, AXIN2 and LGR5. LGR5 is a colon and lung cancer
stem cell marker55,56, and its expression reﬂects stemness-
like properties of cancer cells (Fig. 5e and Supplementary
Fig. S9d). Moreover, we conﬁrmed that the drug combi-
nations reduced the ATP levels in cancer cells, but not in
non-cancer cell lines (HEK293T and MRC5, Supple-
mentary Fig. S9e). DDIT3 is also a potent inducer of
apoptosis48, and the selected drug pairs strongly coop-
erated in reducing viability of various cancer cell lines of
different origin, with no substantial effect in non-cancer
cell lines (Fig. 5f, and Supplementary Fig. S10a). We ruled
out that this effect was mediated by reactive oxygen
species (ROS) (Supplementary Fig. S10b).
Finally, the Nigericin/Rotenone combination lowered
pHi in vivo (P= 0.043) in a xenograft tumor model with
DLD1EC-GFP/mCHERRY colon cancer cells (Fig. 5g), there-
fore, providing an additional evidence that the drug
combination utilized the same mechanism in vivo that
was found for Metformin (Fig. 4c). Mechanistic interac-
tions of the components causing inhibition of Wnt sig-
naling are summarized in Fig. 6. Combination of dual
effects on cellular membrane property and energy meta-
bolism provides a unique opportunity for cancer cell
speciﬁc targeting. Upon treatment (that lasts about 3 days
for the most of the tested cell lines), differences between
normal and cancer cells become more and more pro-
nounced in terms of ATP level and pHi. We assume that
this causes multiple proteins misfolding in the acidiﬁed
intracellular compartment inducing the UPR and DDIT3,
blocking Wnt signaling and activating apoptosis.
Discussion
In this study, we established that SOX4 is induced by
Wnt signaling in number of human cancer cell lines of
different entities (Fig. 1). It has been shown before that
SOX4 also mediates TGFβ signaling during cancer pro-
gression57,58. This relevance to cancer development,
involvement in at least two major cancer cell signaling
pathways ˗ Wnt and TGFβ ˗ makes SOX4 a good candi-
date to be used as a marker gene suitable for assessment
of anticancer treatments. Using SOX4, we discovered that
Metformin acts as Wnt signaling inhibitor (Fig. 2 and
Fig. 3). We also revealed an ability of Metformin to trigger
pHi drop in live cells in vitro and in vivo (Fig. 4a-c). We
speculate that this effect underlies the universal anti-
cancer property of Metformin. Despite earlier observa-
tions concerning acidiﬁcation caused by Metformin49,59,
its ability to induce DDIT344, its MCI inhibitor property60,
and ability to deplete ATP15, a thorough analysis of
intracellular pH dynamics upon Metformin treatment had
not been performed. Applying live cell intracellular pH
sensor assay, we found that any other tested MCI inhi-
bitors also induced pHi drop (Supplementary Fig. S7a). A
straightforward conclusion about reduction of ATP levels
due to inhibition of MCI15 led us to an idea that ATP
depletion would therefore impair defendant proton
pumps function. This in turn would lead to misbalance
between H+ leakage from outer acidiﬁed microenviron-
ment to intracellular compartment and enhanced
requirement for extrusion H+ to outer space. We can
speculate that a similar effect on pHi, albeit to lesser
extent, could also underlie the anti-diabetes properties of
Metformin. Consistent with this idea, it has been reported
that other MCI inhibitors also have anti-diabetic
properties61.
Additionally, we found that inhibition of Wnt signaling
by intracellular acidiﬁcation was not exclusive to MCI
inhibitors. Inhibition of lactic acid extrusion by a broad
MCT inhibitor was able to lower pHi and block Wnt
signaling (Supplementary Fig. S8). This suggests that any
treatment resulting in the pHi drop would also block Wnt
signaling.
Mechanistically, intracellular acidiﬁcation inhibits Wnt
signaling via the Unfolded Protein Response linked to the
drop of ATP level. Intracellular acidiﬁcation induces
DDIT3, an endogenous Wnt signaling inhibitor (Fig. 3
and Supplementary Fig. S4a-c), which disrupts the TCF4/
β-catenin activation complex (Fig. 2d). In addition, upon
acidiﬁcation, binding of TCF4, as well as CBP/p300, to
SOX4 promoter was impaired (Fig. 2). These events
blocked the Wnt response, and importantly, regardless of
β-catenin accumulation (Fig. 1a and Fig. 5c), possibly
involving β-catenin-independent Wnt/STOP signaling62.
DDIT3 induction upon drug treatments was transient
(Supplementary Fig. S9c), while the inhibition of Wnt
signaling was persistent. This suggests that additional
components of the UPR or the apoptotic cascade induced
by DDIT363 are involved in persistent Wnt signaling
suppression and growth inhibition in cancer cell lines
(Fig. 5f and Supplementary Fig. S10a).
Previously, Metformin’s suppressive effect on triple
negative breast cancer cells was linked to KLF5 tran-
scription factor degradation through drop of cAMP and
inactivation of PKA64. Intracellular acidiﬁcation and ATP
depletion could be upstream events that target to degra-
dation not only SOX4 but also other transcription factors,
such as KLF5.
Based on insights into a link between MCI inhibitors
and intracellular pH, we suggested an auto-enhancing
cycle inﬂicted by a combination of ionophore and MCI
inhibitor drugs, which would speciﬁcally entrap cancer
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cell, - a ‘Warburg Trap’. Why would MCI inhibitors affect
glycolysis-addicted cancer cells? The phenomenon of
cancer cells being more sensitive to mitochondrial inhi-
bitors compared to non-cancer ones does not have a clear
explanation yet65. Recently, it has been found that in
cancer cells the ratio between glycolysis and OXPHOS
rates depend on pHe: the more acidic pHe is in tumor
environment, the further cellular metabolism is shifted
towards OXPHOS from glycolysis66. Similarly, it has been
observed that local lactic acidosis in tumor tissue pro-
motes a transition to a non-glycolytic mode67. MCI
inhibitory component of the Warburg Trap restricts
cancer cell from escaping towards OXPHOS, when the
microenvironment is acidiﬁed. Upon such a treatment,
tumor cells experience both a low pHi and drop in ATP
level, leading to cell death.
We provide a molecular mechanism for the Warburg
Trap action: the pHi drop induced by ionophore drug is
accompanied by loss of ATP (Supplementary Fig. S9e).
This in turn induces ER stress with subsequent DDIT3
induction by the UPR (Fig. 5c). The role of DDIT3 as
endogenous Wnt inhibitor is currently underestimated
because of misinterpreted observation on the absence of
clear loss-of-function (LOF) phenotype in development of
Xenopus laevis45 and mouse embryos68. Indeed, DDIT3
LOF was found to have an effect only upon ER stress.
Consistent with this, DDIT3 mediates Metformin and the
Warburg Trap effects only once the UPR is activated
(Fig. 3a-c and Fig. 5d).
While our results strongly support a conclusion about
speciﬁcity of the Warburg Trap towards cancer cells, the
results suggest that this was not exclusively via Wnt
inhibition, since SOX4 was repressed regardless of whe-
ther its expression is controlled by Wnt or other cell
signaling pathways, such as TGFβ (Fig. 1b-c and Supple-
mentary Fig. S1e), and this is consistent with DDIT3 being
a global transcriptional repressor with a range of effects.
Yet, Wnt signaling might be more sensitive to the treat-
ment by Metformin and the Warburg Trap drugs in
comparison to other pathways, since it is predominantly
affected in diabetic lung cancer patients taking Metformin
(Fig. 1f-g and Supplementary Fig. S2), and those with
Wnt-addicted tumors had prolonged survival upon Met-
formin intake (Fig. 1g). We therefore suggest that post-
surgery treatment with MCI inhibitors alone or as the
Warburg trap drug combinations could be considered as a
supportive therapy component, especially in cases of
patients with tumors scored high for Wnt signaling, to
prevent their tumor recurrence risk. This would be in
agreement with earlier observations on beneﬁcial effect of
Metformin treatment for cancer patients69. A selective
action of Metformin on Wnt-dependent tumors may help
explain discrepancy in studies demonstrated reporting on
no or negative effects of Metformin intake in diabetic
cancer patients, e.g., in case of non-small cell lung cancer,
NSCLC9.
The main limitation for use of Metformin as an antic-
ancer drug is a requirement to apply it at very high con-
centrations to achieve a signiﬁcant impact in cancer
cells in vitro. As an alternative MCI inhibitor, Phenformin
might also be considered. It was found to be well
tolerated, and in our experiments was effective at lower
concentrations than Metformin (Fig. 5a, and Supple-
mentary Fig. S10a).
Could H+ ionophores have a future to be used for
cancer patients treatment? The H+ ionophore Monensin
is approved by FDA for application in veterinary as an
anticoccidosis drug, and it displays no toxic effects in
many different animals, with concentrations reaching 220
nM in plasma70 (that is 40 times higher than the con-
centrations applied in experiments described here (Fig. 5f,
and Supplementary Fig. S10a)). Another anticoccidosis
drug, H+ ionophore Salinomycin, has been already tested
on cancer patients, and encouraging results have been
reported71. Collectively, these data suggest that H+
ionophores have a good potential to be applied in human.
Of note, application of H+ ionophores, Nigericin and
Salinomycin, has been already suggested for cancer stem
cells targeting, and these drugs have been demonstrated
to sensitize cancer stem cells72. Also, Salinomycin treat-
ment has shown some promising results in medical
practice71. However, a speciﬁcity of such a single treat-
ments remained unresolved.
Our provision of a molecular mechanism for the War-
burg Trap raises the possibility to develop multiple fur-
ther applications, which could also be combined with
routine chemo- and radio-therapies. We speculate that
the Warburg Trap could be used to overcome multiple
drug resistance caused by ATP-dependent extrusion
pumps. Such pumps (ABC transporters73) cannot be
easily inhibited since they are required for normal cells
de-toxication. However, the Warburg Trap approach
could overcome this obstacle and provide targeted inhi-
bition. Of note, ABCB1 and ABCG2 are Wnt-inducible
transporters74 and therefore might be even more sensitive
to the Warburg Trap inhibition.
In addition, the Warburg Trap principle for targeted
anticancer drug design provides a basis for developing
new-formula drugs with optimal pharmacological prop-
erties. Our ﬁndings therefore set a solid basis for in vivo
experiments and development of pre-clinical investiga-
tions that would follow this study.
Collectively, our data provide the mechanistic rationale
for a combination drug-based cancer cell speciﬁc
approach to inhibit Wnt signaling downstream of β-
catenin. This approach offers a new strategy for cancer
cell speciﬁc treatment, especially for Wnt-addicted
tumors such as a colon and lung cancer.
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Materials and methods
Cells, constructs, chemicals, general procedures
Human cell lines of lung: H1299, H1975, H1703, A549;
colon: HCT116, DLD1; breast MDA-MB-231, and pros-
tate PC3 cancers, glioblastoma-like U87MG and mela-
noma A375 were grown in RPMI (Lonza), supplemented
with 11mg/ml sodium pyruvate (Lonza). Murine B16F10
(melanoma) and C2C12 (immortalized normal myoblast)
cell lines, immortalized non-cancer human fetal lung
ﬁbroblast-like MRC5, non-cancer human embryonic
kidney epithelial HEK293T, HEK293 and Phoenix Ampho
human cell lines were grown in DMEM (Lonza). Culture
media for all cell lines were supplied with 10% fetal calf
serum (FCS; Biosera), and 11mg/ml penicillin and
streptomycin (PAA Laboratories GmbH). For cancer cell
lines, to imitate the pHe of tumor microenvironment, cell
culture media were additionally supplemented with 20
mM PIPES and adjusted to pH 6.5; for non-cancer cell
lines, to imitate pHe of non-tumor microenvironment,
cell culture media were additionally supplemented with
20mM HEPES and adjusted to pH 7.5.
Expression vectors for human LRP6, Xenopus tropicalis
β-catenin, TOPFLASH-luciferase reporter were described
before75. Xenopus-wnt8-human-frizzled5 fusion con-
struct76, human DDIT3-luciferase reporter containing two
copies of the C/EBP-ATF binding site in the AARE
(DDIT3-Luc)77 and expression vector for Ecliptic EC-
GFP51 were described before. pRenilla-TK (Promega) was
a commercial construct. Human DDIT3 expression vector
was generated by cloning DDIT3 ORF obtained by RT-
PCR using primers listed in Supplementary Table S2 from
H1299 cells grown in the presence of Metformin for 48 h,
in pCS2+ vector at ClaI/XbaI restriction sites. It also was
sub-cloned into a retroviral expression vector with a Tet-
inducible promoter pMOWSIN-TREl78. Resulting con-
struct, pMOWSIN-TREl-DDIT3, was used in combina-
tion with pMOWS-rtTAM2 encoding the cDNA for
trans-activator protein for retroviral transduction of
selected cell lines using Phoenix Ampho packaging cell
line, as described before79, and individual positive clones
were selected with Puromycin, 48 h after transduction. To
induce DDIT3 production, cells were treated with 5 µg/ml
Doxycycline for 72 h. To create cells expressing pH-
sensitive GFP variant, EC-GFP was sub-cloned in
pMOWSneo-MCS retroviral vector80 at BamHI/EcoRI
sites (with primers listed at Supplementary Table S2).
Transduced cells (H1975 and HEK293) were selected with
Neomycin, 48 h after transduction. To create pMOWS-
EC-GFP/mCherry, Neo-resistance cassette was removed
from pMOWS-Neo-EC-GFP construct with AfeI/HindIII
and substituted with HindIII/ApaI-blunt fragment of
mCherry from pcDNA3.1-H2b-mCherry (a gift from
Robert Benezra (Addgene plasmid 20972)). The resulting
construct was used for retroviral transduction in DLD1,
and individual positive clones were screened for co-
expression of GFP and mCherry with ﬂuorescence
microscope.
Induction with Wnt3a was performed by adding con-
ditioned media (WntCM) at 1:4 ratios to the culture
media for 48 h or as indicated, as described before75.
Drug treatments in cell culture
In all experiments, unless stated otherwise, treatments
were done using following conditions. Mitochondrial
complex I inhibitors: Metformin - 6 mM for 72 h; Rote-
none - 5 nM for 48 h; Papaverine HCl - 0.5 µM for 72 h or
1 µM for 48 h; Phenformin - as indicated, for 72 h; Bay 87-
2243 - as indicated, for 48 h. Ionophores: Nigericin - 10
nM for 48 h; Salinomycin - 10 nM for 72 h; Monensin - 5
nM for 48 h. Other drugs were used at following con-
centrations and time periods, unless stated otherwise:
Bortezomib - 20 nM for 48 h; Tunicamycin - 1–5 µg/ml
for 48 h. Graviola leaves extract was prepared, as descri-
bed before81 (100 mg/ml concentration corresponds to
100mg leaves extracted with 900 mg DMSO) from pow-
dered dry leaves of plant Annona muricata (Moringa
Shop, Germany), applied at concentrations 0.01–0.16 µg/
ml, for 72 h.
3D collagen invasion assay
3D collagen gels were prepared as described82. In brief,
ice-cold 1M HEPES buffer, 0.7M NaOH, 10× PBS pH 8.0
and bovine skin collagen G solution (L1613, Biochrome)
were mixed in 1:1:2:16 ratios, respectively. 35 μl of the
resulting solution were added per well of a ﬂat bottom 96-
well plate (BD 353376). A plate was kept overnight at 4 °C
to allow gelation of the collagen. After gelation, 10,000
cells per well were seeded on top of the matrix, cultured
overnight and stimulated with WntCM. 96 h later, cells
were ﬁxed with 3.7% PFA for 1 h and stained with
Hoechst (Sigma). Imaging was performed using a LSM710
confocal microscope (Carl Zeiss) equipped with EC Plan-
Neoﬂuar DIC 10×/0.3 NA objective lens (Carl Zeiss). For
each well, a 2 × 2 tile z-stack was acquired. Image analysis
was performed using Imaris software (Bitplane). Spots
detection algorithm was applied to assign a spot for
ﬂuorescent intensity of each individual nucleus. Resulting
spots were ﬁltered by their z-position to separate collagen
invaded cells from the cells remained on top of the matrix.
Percentage of invaded cells was used as an output.
Optical measurements of intracellular pH
The assay was done as described83. In brief, cell lines
expressing pH-sensitive EC-GFP or EC-GFP/mCherry,
were densely seeded on 96-well ﬂat-bottom plates
(BD353376). The next day, cells were treated with drugs
for 48 h, or as indicated. Live cells were imaged using
LSM710 confocal microscope (Carl Zeiss) equipped with
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EC Plan-Neoﬂuar DIC 10×/0.3 NA objective lens (Carl
Zeiss). For each well, 2 × 2 tile was acquired. In case of
H1975EC-GFP and HEK293EC-GFP cell lines, 405 nm and
488 nm lasers were used for EC-GFP excitation, and
emission light was collected using 535/50 ﬁlter for each
laser. 488/405 ratios were quantiﬁed using ImageJ (NIH)
software. In case of DLD1EC-GFP/mCHERRY cell line, 485 nm
(EC-GFP) and 538 nm (mCherry) excitation ﬁlters and
510 nm (EC-GFP) and 620 nm (mCherry) emission ﬁlters
were used to collect EC-GFP and mCherry signals,
respectively, using Fluoroscan Ascent microplate reader
(Thermo Fisher Scientiﬁc). To convert 488/405 and 485/
538 (EC-GFP/mCherry) ratios to pHi values, a calibration
curve for each cell line was produced, as described84. In
brief, untreated cells were exposed for 30min to high K+
solutions with different pH (6.2–8.8 range) (140 mM KCl,
1 mM MgCl2, 2 mM CaCl2, 5 mM glucose buffered with
either 40 mM MES or 40 mM Tris) containing 5 µM
Nigericin (Supplementary Fig. S7b, and data not shown).
Each pHi measurement experiment was done with 5–7
biological replicates for every treatment.
PLGA microspheres formulations preparation
To ensure a continuous drug release and avoid high
peak doses after bolus injections into animals, we used
biodegradable polymer, PLGA (poly (lactic-co-glycolic
acid)), as vehicle for the drug formulations. PLGA (lactid:
glycolide (75:25)) (SIGMA or Vornia Biomaterials) for-
mulations consisted of drug in the range of 5–20mg per
1 g of PLGA, as described elsewhere85,86. In brief, 100mg
of PLGA beads were dissolved in 5 ml Dichloromethane
(DCM) together with the selected drug. PLGA/drug
mixture was added drop-wise to 15ml of ice-cold 0.4%
PVA (Polyvinylalcohol) water solution on ice, mixed for 1
h by rotation (600 rpm) using magnet mixer. Formed
emulsion was then left at room temperature on a mixer
until DCM was evaporated (overnight) and subsequently
washed three times with distilled water. Obtained
microsphere beads were segregated according to their size
by centrifugation for 5 min at 209 g, followed by separa-
tion using a 250 µm cell strainer (Thermo Fisher Scien-
tiﬁc). After pelleting, beads were air-dried and additionally
stored in vacuum for at least 24 h, to ensure removal of
traces of DCM. Finally, the beads were weighted and
resuspended in sterile PBS for injections into animals.
Animal experiments
Animal care and all animal experiments were performed
according to the national guidelines and were approved
ﬁrst by an institutional review board/ethics committee
headed by the local animal welfare ofﬁcer (Dr. Michaela
Socher) of the German Cancer Research Center, Heidel-
berg, Germany. All experiments were in addition
approved by the responsible national authority, the local
Governmental Committee for Animal Experimentation
(Regierungspräsidium Karlsruhe, Germany) under licen-
ses G244/11, G284/15, G195/16, and were carried out
accordingly.
In vivo and ex vivo pHi measurements in xenograft tumors
Five to six-week-old female NMRI-Foxn1nu (Charles
River, Sulzfeld, Germany) were subcutaneously injected
with 2 × 106 H1975EC-GFP human lung cancer cells,
resuspended in 100 µl PBS into the right ﬂank. Eighteen
days after transplantation, once the tumor growth was
detected, mice received drinking water containing 200 µg/
ml Metformin or normal drinking water, as a control, for
7 days. In vivo and ex vivo tumor imaging was performed
with IVIS Lumina III (Perkin Elmer) system using 460 nm
excitation and 520 nm emission ﬁlters and quantiﬁed with
LivingImage software V4.4 (Caliper Life Sciences). For the
experiment, in which pHi changes were induced with a
combination of an ionophore and a MCI inhibitor, nude
female mice were subcutaneously injected with 2 × 106
DLD1EC-GFP/mCHERRY cells resuspended in 100 µl PBS.
When the tumor diameter reached 5 mm, mice were
in vivo imaged with IVIS Lumina III, and the initial
control GFP/mCherry ratios in xenografted tumors were
measured using the appropriate ﬁlter sets. Animals were
randomized into four cohorts (n= 5 mice in each group),
and were intraperitoneally injected, twice per week, either
with 10mg of control PLGA microsphere preparations in
200 µl PBS alone, or with 5 mg PLGA containing either 5
µg Nigericin/mg PLGA or 20 µg Rotenone/mg PLGA
beads, in 100 µl PBS, or the combination of both com-
pounds (10 mg of beads in 200 µl PBS). One week later,
animals were subjected to in vivo imaging, as described
above. During live imaging, the animals were anesthetized
with 5% initiating and 2% maintaining doses of isoﬂurane.
EC-GFP/mCherry values were normalized to the control
treatment and initial control signals.
qRT-PCR
RNA and cDNA were prepared as described87, and
qRT-PCR was performed with UPL probes (Roche) using
LC480 LightCycler (Roche). Details of qPCR primers and
UPL probes used for ampliﬁcation are provided in Sup-
plementary Table S2. mRNA values were normalized to
the housekeeping gene GAPDH (all in vitro experiments),
or ESD (patients’ samples).
Western blot analysis (WB)
Cells were lysed in Triton lysis buffer (TBS (50 mM Tris
pH7.4, 150mM NaCl, 2.7 mM KCl), 1% Triton X-100, 2
mM β-mercaptoethanol (ME), 1 mM MgCl2, 1 × protei-
nase inhibitor cocktail (PIC) (Sigma)) for 5 min on ice.
Lysates were cleared by centrifugation and analyzed by
SDS-PAGE. For β-catenin analysis, cytosolic extracts were
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prepared using Saponin lysis buffer (0.05% saponin, 1 mM
MgCl2, 1 × TBS, 2 mM ME, 1 × PIC), for 30 min on ice.
Antibodies used were: SOX4 (Diagenode cs-129-100), α-
tubulin (Thermo Scientiﬁc, MS-581-P0), DDIT3 (Santa
Cruz sc-575), β-catenin (BD Transduction Laboratories,
610153), and TCF4 (Santa Cruz, sc-166699).
ChIP assay
Chromatin immunoprecipitation assays were done
essentially as described88, with some modiﬁcations. In
particular, after ﬁxation of cells with 1% formaldehyde for
10min, nuclei preparation and washing, chromatin was
sheared in Shearing buffer (25 mM Tris-HCl, pH 8.0; 1
mM EDTA, 0.5 mM EGTA, 2.5 mM sodium pyropho-
sphate, 1 mM PMSF, 1 × PIC) using Covaris S2 (ultra-
sonicator with following settings: Time= 20min, 20%
Duty Cycle, Intensity= 4, 200 cycles per burst), or with
Sonoplus Bandelin (12 times for 30 s, 40% power). Before
immunoprecipitation, Triton X-100 to 1%, SDS to 0.1%
and NaCl to 150 mM were added to the sheared chro-
matin. IP reactions were incubated overnight, and formed
immunocomplexes were recovered using protein A/G
magnetic beads (Pierce). After washings, complexes were
eluted with Proteinase K digestion buffer (20 mM HEPES,
pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5% SDS), and
immunoprecipitated DNA was recovered after digestion
with 400 µg/ml Proteinase K for 1 h at 42 °C, RNase A
treatment and crosslinking reversal. DNA was puriﬁed
and analyzed by qPCR analysis using SYBR Green master
mix (Qiagen QuantiTect) with primers listed in Supple-
mentary Table S2. CBP and p300 antibodies were from
Santa-Cruz Biotechnology (sc-369X and sc-585X ,
respectively), TCF4 and normal IgG were from EMD
Millipore (17-10109 and 12-370, respectively).
Co-immunoprecipitation assay (Co-IP)
Cells were lysed in Triton lysis buffer (TBS (50 mM
Tris pH7.4, 150 mM NaCl, 2.7 mM KCl), 1% Triton X-
100, 1 mM MgCl2, 1 × proteinase inhibitor cocktail
(PIC) (Sigma)) for 20 min on ice. Lysates were cleared by
centrifugation at 2000 g and subjected to immunopre-
cipitation with TCF4 antibody (Millipore, 17-10109)
bound to Protein A/G-PLUS agarose beads (Santa Cruz,
sc-2003) overnight. After washing beads 6 times with
washing buffer (TBS, 0.1% Triton X-100, PIC), immu-
nocomplexes were eluted with Laemmli Sample Buffer
4× (Bio-Rad), resolved in SDS-PAGE and analyzed by
WB.
Patients' tumor samples
All patients underwent a surgery at the Thoraxklinik,
University Hospital Heidelberg.
RNA samples from lung tissues were provided by Lung-
Biobank Heidelberg, a member of the BioMaterialBank
Heidelberg (BMBH), and the biobank platform of the
German Center for Lung Research (DZL). All patients
gave written informed consent for the use of their bio-
materials for research purposes. The protocol was
approved by the ethics committee of the University of
Heidelberg. Tissues were snap-frozen within 30min after
resection and stored at −80 °C until the time of analysis.
Tumor histology was classiﬁed according to the 3rd
edition of the World Health Organization classiﬁcation
system89. A brief summary of patients’ clinical data is
presented in Supplementary Table S1.
Isolation of tissue samples RNA
Total RNA was isolated using an RNeasy Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s
instruction, with the DNase I treatment step included.
The quality of total RNA from patients’ tissues was
assessed with an Agilent 2100 Bioanalyzer and Agilent
RNA 6000 Nano Kit (Agilent Technologies, Boeblingen,
Germany). RNA was considered sufﬁcient for further
analyses if it had an RNA integrity number (RIN) of at
least 8.0.
Luciferase reporter assays
Luciferase reporter assays were carried out in 96-well
plates, as described before75. In brief, a total of 100 ng of
DNA was transfected per well, including either 5 ng
TOPFLASH with 1 ng pRenilla-TK or 10 ng human
DDIT3-luciferase reporter (DDIT3-luc) and, when indi-
cated, 4 ng human LRP6, 4 ng Xenopus-wnt8-human-
frizzled5 fusion, 0.5 ng Xenopus tropicalis β-catenin and
70 ng human DDIT3. Drug treatments were applied next
day after transfection, and cells were treated for 48 h prior
to luciferase activity measurements with the Dual luci-
ferase system (Promega).
Cell viability assay
Indicated cells were treated with indicated drug com-
binations for 48 h in conditions imitating tumor envir-
onment, in case of cancer cell lines, or in conditions of
non-tumor environment, in case of non-cancer cell lines.
After the treatment, cells were analyzed for cell viability
using CellTiter-Glo® Cell Viability Assay (Promega),
according to the manufacturer’s recommendations. For
each treatment, fractions (%) of viable cells were quanti-
ﬁed, with untreated viable cells set as 100%. Each
experiment was repeated at least twice, with 6 biological
replicates for each condition.
Measurement of cellular ATP levels
ATP levels were quantitated by the CellTiter-Glo® Cell
Viability Assay kit (Promega), according to the manu-
facturer’s recommendations. In brief, serial dilutions of
ATP solutions were prepared, and the luminescence
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signal was recorded to build a calibration curve. Cells
were treated, as described above for the cell viability
assay, and an absolute ATP amount per cell was quanti-
ﬁed using the calibration curve. Each measurement was
repeated at least twice, with 6 biological replicates for
each condition.
siRNA transfection experiments
For mRNA knock-down experiments, cells in 6-well
format were transfected with 50 nM of non-targeting
control siRNA or with corresponding ON-TARGET
SMARTpool siRNA or siGENOME SMARTpool siRNA
(all from Dharmacon, except for DDIT3 siRNA, which
was from Santa-Cruz) using DharmaFECT1 reagent
(Dharmacon) following the manufacturer protocol. 24 h
after siRNA transfection, the cells were treated with
WntCM, and subjected to selected drug treatment, as
indicated. Cells were harvested in 72–120 h post-trans-
fection, depending on experiment, for Western blot and
qRT-PCR analyses. For each experiment with siRNA
transfection, mRNA knockdown efﬁciencies were quan-
tiﬁed using qRT-PCR, and a targeted mRNA levels were
found to be reduced down to at least 15–20% of the one in
a control treatment with non-targeting siRNA (Supple-
mentary Fig. S4, and data not shown).
CRISPR-mediated knock-out of DDIT3 gene
H1975 cells were stably transfected with Cas9 under
Blasticidin selection (pHCSVBlast-Cas9, Dharmacon).
Positive clone was selected using detection of Cas9 in WB
using Cas9 antibody (Novus NBP2-36440, clone 7A9-
3A3). Cas9 expressing cells were transfected with a 1:1
molar ratio mix of tracrRNA (Dharmacon product
U-002000-120) and DDIT3-speciﬁc crRNA (5´CUG
GUAUGAGGACCUGCAAGGUUUUAGAGCUAUGCU
GUUUUG 3´, designed with CRISPR RNA Conﬁgurator
tool, Dharmacon) using DarmaFECT1 (Dharmacon).
5 days later, cells were harvested and plated at low density.
Individual clones were treated with DDIT3-inducing
drugs and assayed by WB, 48 h later (Supplementary
Fig. S5e). Clone that failed to produce DDIT3 protein, was
selected and veriﬁed with successive sequencing. The
effective mutation is highlighted in Supplementary
Fig. S5e.
Statistical analysis
GraphPad Prism software was used for most statistical
analyses. Two-way ANOVA tests were used to assess
statistical signiﬁcance in cell invasion, pHi properties
between treated and untreated cell lines in vitro. In vivo
changes of pHi in tumor xenograft tissues were tested
with unpaired t-test. Cell invasion properties and ATP
amount changes were assessed using one-way ANOVA
Dunnett’s multiple comparison tests.
Correlations between expression of mRNA of interest
and of Wnt target genes in patients’ tumor samples were
carried out using non-parametric correlation tests, and
Spearman’s rank correlation coefﬁcients were calculated.
For assessment of patients’ survival data, Kaplan–Meier
curves were built, and log-rank (Mantel–Cox) test was
calculated using IBM SPSS statistics software (V22.0). For
ﬁnding an optimal cut-off level and survival data stratiﬁ-
cation, ADAM statistical software package (DKFZ, Hei-
delberg) utilizing Critlevel procedure was used90. In brief,
for the combined patients cohort (including both
Metformin-taking and not taking Metformin lung cancer
patients), the optimal expression cut-off levels for the
tested genes were calculated and used as new variants
(0= below threshold, 1= above threshold), and these
parameters were applied to assess the survival data. Only
for the Metformin-taking lung cancer patients cohort
stratiﬁcation by AXIN2 expression (with a cut-off at 1.02),
and not for the other tested genes, revealed differences in
their survival that were found to be signiﬁcant (P= 0.046).
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